The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
The case of complement activation in COVID-19 multiorgan impact
Open accessAbstract
The novel coronavirus disease COVID-19 originates in the lungs, but it may extend to other organs, causing, in severe cases, multiorgan damage, including cardiac injury and acute kidney injury. In severe cases, the presence of kidney injury is associated with increased risk of death, highlighting the relevance of this organ as a target of SARS-CoV-2 infection. COVID-19–associated tissue injury is not primarily mediated by viral infection, but rather is a result of the inflammatory host immune response, which drives hypercytokinemia and aggressive inflammation that affect lung parenchymal cells, diminishing oxygen uptake, but also endothelial cells, resulting in endotheliitis and thrombotic events and intravascular coagulation. The complement system represents the first response of the host immune system to SARS-CoV-2 infection, but there is growing evidence that unrestrained activation of complement induced by the virus in the lungs and other organs plays a major role in acute and chronic inflammation, endothelial cell dysfunction, thrombus formation, and intravascular coagulation, and ultimately contributes to multiple organ failure and death. In this review, we discuss the relative role of the different complement activation products in the pathogenesis of COVID-19–associated tissue inflammation and thrombosis and propose the hypothesis that blockade of the terminal complement pathway may represent a potential therapeutic option for the prevention and treatment of lung and multiorgan damage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884 · cited 2×
“These events originate in the lungs but may extend to other organs, as documented by reports that patients with severe coronavirus disease 2019 (COVID-19) often develop multiorgan damage, including cardiac injury and acute kidney injury (AKI).(3,4) In a very recent published article, Cheng et al.”
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Endothelial cell infection and endotheliitis in COVID-19
Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., Mehra, M. R., Schuepbach, R. A., Ruschitzka, F., & Moch, H. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30937-5 · Cited by 6,358
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,735
Tang, N., Li, D., Wang, X., & Sun, Z. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14768 · Cited by 5,662
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750
Tang, N., Bai, H., Chen, X., Gong, J., Li, D., & Sun, Z. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14817 · Cited by 3,559
COVID-19 and Italy: what next?
Remuzzi, A., & Remuzzi, G. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30627-9 · Cited by 3,119
Self-citationKidney disease is associated with in-hospital death of patients with COVID-19
Cheng, Y., Luo, R., Wang, K., Zhang, M., Wang, Z., Dong, L., Li, J., Yao, Y., Ge, S., & Xu, G. (2020) · Kidney International · doi:10.1016/j.kint.2020.03.005 · Cited by 2,941
Bikdeli, B., Madhavan, M. V., Jimenez, D., Chuich, T., Dreyfus, I., Driggin, E., Nigoghossian, C. D., Ageno, W., Madjid, M., Guo, Y., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.031 · Cited by 2,885
Magro, C., Mulvey, J. J., Berlin, D., Nuovo, G., Salvatore, S., Harp, J., Baxter-Stoltzfus, A., & Laurence, J. (2020) · Translational Research · doi:10.1016/j.trsl.2020.04.007 · Cited by 2,183
Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China
Su, H., Yang, M., Wan, C., Yi, L.-X., Tang, F., Zhu, H.-Y., Yi, F., Yang, H.-C., Fogo, A. B., Nie, X., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.04.003 · Cited by 1,755
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
Legendre, C. M., Licht, C., Muus, P., Greenbaum, L. A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D. J., Delmas, Y., Douglas, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208981 · Cited by 1,586
Self-citationCarsana, L., Sonzogni, A., Nasr, A., Rossi, R. S., Pellegrinelli, A., Zerbi, P., Rech, R., Colombo, R., Antinori, S., Corbellino, M., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30434-5 · Cited by 1,396
[A pathological report of three COVID-19 cases by minimal invasive autopsies].
Yao, X. H., Li, T. Y., He, Z. C., Ping, Y. F., Liu, H. W., Yu, S. C., Mou, H. M., Wang, L. H., Zhang, H. R., Fu, W. J., et al. (2020) · PubMed · doi:10.3760/cma.j.cn112151-20200312-00193 · Cited by 963
Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection
Diao, B., Wang, C., Wang, R., Feng, Z., Zhang, J., Yang, H., Tan, Y., Wang, H., Wang, C., Liu, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22781-1 · Cited by 900
Overview of complement activation and regulation
Noris, M., & Remuzzi, G. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.08.001 · Cited by 864 · cited 4×
“In patients with COVID-19, eculizumab, by preventing the cleavage of C5, could exert a favorable effect by blocking the proinflammatory and prothrombotic actions of the terminal products of the complement cascade activated by SARS-CoV2, while preserving the activity of early complement components that are important fo…”
InfluentialSelf-citationCOVID-19 and Kawasaki Disease: Novel Virus and Novel Case
Jones, V. G., Mills, M., Suarez, D., Hogan, C. A., Yeh, D., Segal, J. B., Nguyen, E. L., Barsh, G. R., Maskatia, S., & Mathew, R. (2020) · Hospital Pediatrics · doi:10.1542/hpeds.2020-0123 · Cited by 766
Sims, P. J., Faioni, E. M., Wiedmer, T., & Shattil, S. J. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)81346-7 · Cited by 673
Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis
Gralinski, L. E., Sheahan, T. P., Morrison, T. E., Menachery, V. D., Jensen, K., Leist, S. R., Whitmore, A., Heise, M. T., & Baric, R. S. (2018) · mBio · doi:10.1128/mbio.01753-18 · Cited by 655
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis
Jayne, D. R. W., Bruchfeld, A. N., Harper, L., Schaier, M., Venning, M. C., Hamilton, P., Burst, V., Grundmann, F., Jadoul, M., Szombati, I., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016111179 · Cited by 607
Kidney involvement in COVID-19 and rationale for extracorporeal therapies
Ronco, C., & Reis, T. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0284-7 · Cited by 531
Complement as a target in COVID-19?
Risitano, A. M., Mastellos, D. C., Huber-Lang, M., Yancopoulou, D., Garlanda, C., Ciceri, F., & Lambris, J. D. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0320-7 · Cited by 484
Gao, T., Zhu, L., Liu, H., Zhang, X., Wang, T., Fu, Y., Li, H., Dong, Q., Hu, Y., Zhang, Z., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01133-5 · Cited by 436
Franks, T. J., Chong, P. Y., Chui, P., Galvin, J. R., Lourens, R. M., Reid, A. H., Selbs, E., Mcevoy, C. P. L., Hayden, C. D. L., Fukuoka, J., et al. (2003) · Human Pathology · doi:10.1016/s0046-8177(03)00367-8 · Cited by 415
STEC-HUS, atypical HUS and TTP are all diseases of complement activation
Noris, M., Mescia, F., & Remuzzi, G. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.195 · Cited by 383
Self-citationUltrastructural Evidence for Direct Renal Infection with SARS-CoV-2
Farkash, E. A., Wilson, A. M., & Jentzen, J. M. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020040432 · Cited by 350
Clinical promise of next-generation complement therapeutics
Mastellos, D. C., Ricklin, D., & Lambris, J. D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0031-6 · Cited by 343
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy
Noris, M., Galbusera, M., Gastoldi, S., Macor, P., Banterla, F., Bresin, E., Tripodo, C., Bettoni, S., Donadelli, R., Valoti, E., et al. (2014) · Blood · doi:10.1182/blood-2014-02-558296 · Cited by 341
Self-citationAkaike, T., Ando, M., Oda, T., Doi, T., Ijiri, S., Araki, S., & Maeda, H. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114499 · Cited by 332
Diurno, F., Numis, F. G., Porta, G., Cirillo, F., Maddaluno, S., Ragozzino, A., Negri, P. D., Gennaro, C. D., Pagano, A., Allegorico, E., et al. (2020) · PubMed · doi:10.26355/eurrev_202004_20875 · Cited by 326
Tedesco, F., Pausa, M., Nardon, E., Introna, M., Mantovani, A., & Dobrina, A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.9.1619 · Cited by 318
Review: Viral infections and mechanisms of thrombosis and bleeding
Goeijenbier, M., van Wissen, M., van de Weg, C., Jong, E., Gerdes, V. E. A., Meijers, J. C. M., Brandjes, D. P. M., & van Gorp, E. C. M. (2012) · Journal of Medical Virology · doi:10.1002/jmv.23354 · Cited by 299
Inhibiting the C5–C5a receptor axis
Woodruff, T. M., Nandakumar, K. S., & Tedesco, F. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.04.014 · Cited by 289
Mannose-Binding Lectin in Severe Acute Respiratory Syndrome Coronavirus Infection
Ip, W. K. E., Chan, K. H., Law, H. K. W., Tso, G. H. W., Kong, E. K. P., Wong, W. H. S., To, Y. F., Yung, R. W. H., Chow, E. Y., Au, K. L., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/429631 · Cited by 284
C5a Induces Tissue Factor Activity on Endothelial Cells
Ikeda, K., Nagasawa, K., Horiuchi, T., Tsuru, T., Nishizaka, H., & Niho, Y. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1655974 · Cited by 272
Will Complement Inhibition Be the New Target in Treating COVID-19–Related Systemic Thrombosis?
Campbell, C. M., & Kahwash, R. (2020) · Circulation · doi:10.1161/circulationaha.120.047419 · Cited by 267
Complement and viral pathogenesis
Stoermer, K. A., & Morrison, T. E. (2011) · Virology · doi:10.1016/j.virol.2010.12.045 · Cited by 255
Role of C5a in Multiorgan Failure During Sepsis
Huber-Lang, M., Sarma, V. J., Lu, K. T., McGuire, S. R., Padgaonkar, V. A., Guo, R.-F., Younkin, E. M., Kunkel, R. G., Ding, J., Erickson, R., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.2.1193 · Cited by 224
Jiang, Y., Zhao, G., Song, N., Li, P., Chen, Y., Guo, Y., Li, J., Du, L., Jiang, S., Guo, R., et al. (2018) · Emerging Microbes & Infections · doi:10.1038/s41426-018-0063-8 · Cited by 195
Mehlhop, E., & Diamond, M. S. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052388 · Cited by 175
The role of C5a in acute lung injury induced by highly pathogenic viral infections
Wang, R., Xiao, H., Guo, R., Li, Y., & Shen, B. (2015) · Emerging Microbes & Infections · doi:10.1038/emi.2015.28 · Cited by 170
Keragala, C. B., Draxler, D. F., McQuilten, Z. K., & Medcalf, R. L. (2018) · British Journal of Haematology · doi:10.1111/bjh.15062 · Cited by 170
Wijnsma, K. L., ter Heine, R., Moes, D. J. A. R., Langemeijer, S. M. C., Schols, S. E. M., Volokhina, E. B., van den Heuvel, L. P., Wetzels, J. F. M., van de Kar, N. C. A. J., & Brüggemann, R. J. M. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00742-8 · Cited by 139
Sun, S., Zhao, G., Liu, C., Wu, X., Guo, Y., Yu, H., Song, H., Du, L., Jiang, S., Guo, R., et al. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0428oc · Cited by 118
The Role of the Complement System in Acute Kidney Injury
McCullough, J. W., Renner, B., & Thurman, J. M. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.08.005 · Cited by 112
Garcia, C. C., Weston‐Davies, W., Russo, R. C., Tavares, L. P., Rachid, M. A., Alves-Filho, J. C., Machado, A. V., Ryffel, B., Nunn, M. A., & Teixeira, M. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064443 · Cited by 108
Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria
van Bijnen, S. T. A., van Heerde, W. L., & Muus, P. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04562.x · Cited by 105
O’Brien, K., Morrison, T. E., Dundore, D. Y., Heise, M. T., & Schultz‐Cherry, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017377 · Cited by 99
Expression of the anaphylatoxin C5a receptor in non-myeloid cells
Zwirner, J., Fayyazi, A., & Götze, O. (1999) · Molecular Immunology · doi:10.1016/s0161-5890(99)00109-1 · Cited by 95
Sun, S., Zhao, G., Chenfeng, L., Fan, W., Xiaojun, Z., Zeng, L., Guo, Y., Kou, Z., Yu, H., Li, J., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu887 · Cited by 90
Jiang, Y., Li, J., Teng, Y., Sun, H. C., Tian, G., He, L., Li, P., Chen, Y., Guo, Y., Li, J., et al. (2019) · Viruses · doi:10.3390/v11010039 · Cited by 76
Ohta, R., Torii, Y., Imai, M., Kimura, H., Okada, N., & Ito, Y. (2011) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2011.00309.x · Cited by 65
Bettoni, S., Galbusera, M., Gastoldi, S., Donadelli, R., Tentori, C., Spartà, G., Bresin, E., Mele, C., Alberti, M., Tortajada, A., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601121 · Cited by 63
Self-citationKilgore, K. S., Ward, P. A., & Warren, J. S. (1998) · Inflammation · doi:10.1023/a:1022362413939 · Cited by 57
Ling, M. T., Tu, W., Han, Y., Mao, H., Chong, W. P., Guan, J. Z., Liu, M., Lam, K. T., Law, H., Peiris, M. J. S., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir691 · Cited by 53
Angiotensin-converting enzyme 2 and renal disease
Williams, V. R., & Scholey, J. W. (2017) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000378 · Cited by 53
Current pharmacotherapeutic options for myasthenia gravis
Barnett, C., Tabasinejad, R., & Bril, V. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1682548 · Cited by 27
The COVID Coagulopathy Conundrum: Facts, Fiction, and Fantasy
Lee, A. Y. Y., & Kreuziger, L. B. (2020) · The Hematologist · doi:10.1182/hem.v17.4.10401 · Cited by 1
Cited by
Aging in COVID-19: Vulnerability, immunity and intervention
Chen, Y., Klein, S. L., Garibaldi, B. T., Li, H., Wu, C., Osevala, N. M., Li, T., Margolick, J. B., Pawelec, G., & Leng, S. X. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101205 · Cited by 1,007
Nadim, M. K., Forni, L. G., Mehta, R. L., Connor, M. J., Liu, K. D., Ostermann, M., Rimmelé, T., Zarbock, A., Bell, S., Bihorac, A., et al. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00356-5 · Cited by 690
Immunity, endothelial injury and complement-induced coagulopathy in COVID-19
Perico, L., Benigni, A., Casiraghi, F., Ng, L. F. P., Renia, L., & Remuzzi, G. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00357-4 · Cited by 607
Self-citationKidney involvement in COVID-19 and rationale for extracorporeal therapies
Ronco, C., & Reis, T. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0284-7 · Cited by 531
Xu, S.-W., Ilyas, I., & Weng, J.-P. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00998-0 · Cited by 440
Metadata
- Authors
- Noris, M., Benigni, A., & Remuzzi, G.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 98
- Issue
- 2
- Pages
- 314-322
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W3027964178
- Cited by
- 335
- References
- 60
- FWCI
- 20.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.